Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 133-140

  Maki, Yuho ^a   Soh, Junichi ^a   Ichimura, Kouichi ^a   Shien, Kazuhiko ^a   Furukawa, Masashi ^a   Muraoka, Takayuki ^a   Tanaka, Norimitsu ^a   Ueno, Tsuyoshi ^a   Yamamoto, Hiromasa ^a   Asano, Hiroaki ^a   Tsukuda, Kazunori ^a   Toyooka, Shinichi ^a   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Early stage lung adenocarcinoma; Glucose transporter isoform 1; Ki 67

Indexed keywords

GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EARLY CANCER; EGFR GENE; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOENZYME TECHNIQUES; INTERNATIONAL AGENCIES; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872856518     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2087     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299, 2005.
4. van Rens MT, de la Riviere AB, Elbers HR and van Den Bosch JM: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117: 374-379, 2000.
5. Koike T, Kimura N, Miyazaki K, et al: Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci USA 101: 8132-8137, 2004.
6. Wood IS and Trayhurn P: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89: 3-9, 2003.
7. Kalir T, Wang BY, Goldfischer M, et al: Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 94: 1078-1082, 2002.
8. Carvalho KC, Cunha IW, Rocha RM, et al: GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (São Paulo) 66: 965-972, 2011.
9. Koukourakis MI, Giatromanolaki A, Bougioukas G and Sivridis E: Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 6: 1476-1479, 2007.
10. Wang K, Sun Y and Wang T: The prognostic significance of GLUT1 expression in stage I and II NSCLC. Zhongguo Fei Ai Za Zhi 5: 451-453, 2002 (In Chinese).
11. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
12. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P and Collan Y: Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48: 674-682, 2006.
13. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
14. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
15. Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P and Ferno M: The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 23: 251-259, 2010.
16. Minami K, Saito Y, Imamura H and Okamura A: Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38: 51-57, 2002.
17. Tungekar MF, Gatter KC, Dunnill MS and Mason DY: Ki-67 immunostaining and survival in operable lung cancer. Histopathology 19: 545-550, 1991.
18. Simony J, Pujol JL, Radal M, Ursule E, Michel FB and Pujol H: In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res 50: 4382-4387, 1990.
19. Mehdi SA, Etzell JE, Newman NB, Weidner N, Kohman LJ and Graziano SL: Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer 20: 99-108, 1998.
20. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655, 2005.
21. Ichihara S, Toyooka S, Fujiwara Y, et al: The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120: 1239-1247, 2007.
22. Toyooka S, Mitsudomi T, Soh J, et al: Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 59: 527-537, 2011.
23. Travis WD, Brambilla E, Noguchi M, et al: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285, 2011.
24. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC (eds): World Health Organization Classification of Tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon, 2004.
25. Rami-Porta R, Crowley JJ and Goldstraw P: The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15: 4-9, 2009.
26. Jun YJ, Jang SM, Han HL, Lee KH, Jang KS and Paik SS: Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas. World J Gastroenterol 17: 1866-1873, 2011.
27. Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM and Bigotti G: Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res 27: 34, 2008.
28. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
29. Dowsett M, Nielsen TO, A'Hern R, et al: Assessment of Ki67 in Breast Cancer: recommendations from the international Ki67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664, 2011.
30. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ: Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
31. Colozza M, Sidoni A and Piccart-Gebhart M: Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11: 414-415, 2010.
32. Jonat W and Arnold N: Is the Ki-67 labelling index ready for clinical use? Ann Oncol 22: 500-502, 2011.
33. Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12: 43-48, 2006.
34. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005.
35. Suehisa H, Toyooka S, Hotta K, et al: Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 25: 3952-3957, 2007.
36. Watanabe S, Watanabe T, Arai K, Kasai T, Haratake J and Urayama H: Results of wedge resection for focal bronchiolo-alveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 73: 1071-1075, 2002.
37. Yamada S and Kohno T: Video-assisted thoracic surgery for pure ground-glass opacities 2 cm or less in diameter. Ann Thorac Surg 77: 1911-1915, 2004.
38. Sasaki H, Shitara M, Yokota K, et al: Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Rep 5: 599-602, 2012.
39. Yun J, Rago C, Cheong I, et al: Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325: 1555-1559, 2009.
40. Furudoi A, Tanaka S, Haruma K, et al: Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 60: 162-169, 2001.
41. Noguchi M, Morikawa A, Kawasaki M, et al: Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75: 2844-2852, 1995.
42. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S and Ochiai A: Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer 29: 179-188, 2000.
43. Yoshida J, Nagai K, Yokose T, et al: Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg 129: 991-996, 2005.